Studied in registered human trials with published pharmacokinetic data, but not approved. Dosing outside a trial protocol has no established safety margin.
A rat PK study (Kalenikova et al., Vopr Med Khim 1988, PMID 3369130) describes the plasma curve as a three-exponential function after IV 3H-dalargin but the accessible English abstract states no numeric half-life. The commonly repeated ~35 min figure appears only on vendor sites and could not be verified, so it is NOT recorded.
No standardized mcg dosing regimen found on allowed hosts. Russian/Ukrainian clinical literature describes injection, endonasal electrophoresis, and ultraphonophoresis routes for GI/skin indications, but exact per-dose amounts were not extractable from the fetched abstracts.
Almost entirely Russian/Ukrainian-lineage literature (1980s-2000s), often without English full text or modern replication. No Western double-blind RCTs found. Clinical-use citations are small regional studies. Sequence and MW 725.8 Da confirmed on PubChem (CID 6917894).
Human clinical use is documented only in regional (Russian/Ukrainian) literature, largely for GI indications, not for research/performance/self-administration contexts. No Western pharmacovigilance, no FDA/EMA safety review. Absence of reported harm in older regional literature is not evidence of safety in other populations, doses, or routes.